In a significant development, the DEA is considering rescheduling cannabis from a Schedule I to a Schedule III drug, potentially reshaping the regulatory landscape and impacting research.
The cannabis industry depends on trust, transparency, and ethical business practices to function properly. When a company provides months of professional services and is not compensated as agreed, it raises serious concerns about financial accountability within the market.